Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

贝伐单抗 阿替唑单抗 医学 内科学 危险系数 肿瘤科 不利影响 肝细胞癌 实体瘤疗效评价标准 胃肠病学 临床研究阶段 临床试验 无容量 癌症 置信区间 化疗 免疫疗法
作者
Masatoshi Kudo,Kaoru Tsuchiya,Yu‐Yun Shao,Richard S. Finn,Peter R. Galle,Michel Pierre Ducreux,Ann‐Lii Cheng,Tatsuya Yamashita,Hironori Koga,Ryosuke Take,Kyoko Yamada,Takashi Asakawa,Yuki Nakagawa,Masafumi Ikeda
出处
期刊:Liver cancer [Karger Publishers]
卷期号:13 (4): 401-412 被引量:22
标识
DOI:10.1159/000535501
摘要

Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs). Methods: Patients in IMbrave150 who were randomized to atezolizumab + bevacizumab and received treatment for ≥6 months (to reduce immortal time bias) were included in group A-1 if bevacizumab had ever been skipped due to bevacizumab AESIs or to group A-2 otherwise. Efficacy analyses included overall survival (OS) and progression-free survival (PFS) by whether bevacizumab was skipped (group A-1 vs. A-2). PFS was evaluated per independent review facility (IRF)-assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and HCC-modified RECIST (IRF-HCC mRECIST). Safety was also evaluated. Results: Of the 210 patients who received ≥6 months of atezolizumab + bevacizumab, 69 were assigned to group A-1 and 141 to A-2. At data cutoff (August 20, 2020), hazard ratio (HR) for OS was 1.04 (95% CI: 0.64, 1.69) for group A-1 versus A-2. HR for PFS was 1.07 (95% CI: 0.74, 1.55) per IRF-assessed RECIST 1.1 and 1.10 (95% CI: 0.76, 1.59; 15.5 vs. 9.7 months) per IRF-HCC mRECIST for group A-1 versus A-2. Safety profiles for atezolizumab and bevacizumab were largely similar between groups. More group A-1 patients had grade 3/4 adverse events. A separate analysis investigating the impact of immortal time bias in patients who received ≥3 months of atezolizumab + bevacizumab supported the appropriateness of the ≥6-month landmark analysis. Discussion/Conclusion: Efficacy was similar between patients who skipped bevacizumab due to bevacizumab AESIs and those who did not. Although this comparison was nonrandomized and exploratory, results suggest that skipping bevacizumab due to bevacizumab AESIs did not considerably impact the efficacy and safety of atezolizumab + bevacizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哭哭发布了新的文献求助10
刚刚
刚刚
随机完成签到,获得积分10
刚刚
日桉发布了新的文献求助10
1秒前
1秒前
Ronnie完成签到 ,获得积分10
1秒前
drizzle发布了新的文献求助10
2秒前
Sarah完成签到,获得积分10
2秒前
大模型的应助被luojia采纳,获得10
2秒前
找论文的Q完成签到,获得积分10
2秒前
SSSS完成签到,获得积分10
3秒前
AAA发布了新的文献求助30
3秒前
4秒前
5秒前
5秒前
默客发布了新的文献求助10
5秒前
8秒前
脑洞疼的应助被南乔星采纳,获得10
8秒前
9秒前
阿七发布了新的文献求助10
10秒前
彩色乐儿发布了新的文献求助10
10秒前
11秒前
RP-H完成签到,获得积分10
11秒前
12秒前
13秒前
JamesPei的应助被水天需采纳,获得10
13秒前
嘻嘻哈哈的应助被sjk采纳,获得10
13秒前
大碗宽面完成签到,获得积分10
13秒前
Orange的应助被lsq108采纳,获得10
14秒前
西红柿呀完成签到,获得积分20
15秒前
慕青的应助被cc采纳,获得10
15秒前
16秒前
去向未来发布了新的文献求助10
16秒前
16秒前
英俊的铭的应助被芊芊君子采纳,获得10
16秒前
粥末就放假完成签到,获得积分10
17秒前
17秒前
17秒前
17秒前
zeqian发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648